Pyoderma gangrenosum

MolecuLight Clinical Research Featured at the Upcoming SAWC Spring 2024 Conference

Retrieved on: 
Mardi, mai 14, 2024
Patient, DX, Fluorescence imaging, Exhibition, Evaluation, General number field sieve, CLASS, SAWC, Education, Pyoderma, FDA, Effectiveness, Publication, Infection, Antibiotic, Madigan Army Medical Center, Symposium, ASC, Pyoderma gangrenosum, Fluorescence, Medical imaging

Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.

Key Points: 
  • Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.
  • The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.
  • In addition to the clinical posters and presentations at SAWC Spring 2024 , the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight booth #312 in the Exhibition Hall.
  • With unmatched clinical evidence including 95 peer-reviewed publications with over 3000 patients, they are used by leading wound care facilities globally.

MolecuLight Clinical Research Featured at the Upcoming SAWC Spring 2024 Conference

Retrieved on: 
Mardi, mai 14, 2024
Patient, DX, Fluorescence imaging, Exhibition, Evaluation, General number field sieve, CLASS, SAWC, Education, Pyoderma, FDA, Effectiveness, Publication, Infection, Antibiotic, Madigan Army Medical Center, Symposium, ASC, Pyoderma gangrenosum, Fluorescence, Medical imaging

TORONTO and ORLANDO, Fla., May 14, 2024 /PRNewswire/ -- - MolecuLight Inc., the pioneer in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, proudly announces the presentation of findings from multiple MolecuLight studies in nine clinical posters at the Symposium on Advanced Wound Care (SAWC) Spring 2024. These studies feature new data demonstrating enhanced diagnostics, targeted debridement, improved healing outcomes, and increased patient engagement facilitated by MolecuLight devices. Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging. The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.

Key Points: 
  • Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.
  • The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.
  • In addition to the clinical posters and presentations at SAWC Spring 2024 , the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight booth #312 in the Exhibition Hall.
  • With unmatched clinical evidence including 95 peer-reviewed publications with over 3000 patients, they are used by leading wound care facilities globally.

Global Infliximab Drug Market to 2031 Set to Expand with Rising Rheumatoid Arthritis Cases - ResearchAndMarkets.com

Retrieved on: 
Mardi, août 29, 2023
Pharmaceutical, Health, Other Health, Infliximab, Lupus, TNF, Prevalence, Eye, Skin, Ankylosing spondylitis, SLE, Inflammation, Multiple sclerosis, Ulcerative colitis, Psoriasis, Crohn's disease, Patient, Hidradenitis suppurativa, Uveitis, Nonsteroidal anti-inflammatory drug, Immune system, Warfarin necrosis, Growth, Pyoderma gangrenosum, Rheumatoid arthritis, Vaccine

The "Global Infliximab Drug Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infliximab Drug Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the global infliximab drug market is driven by the rising number of rheumatoid arthritis cases.
  • The prevalence of rheumatoid arthritis disease is likely to grow at a CAGR of 1.0% in the forecast period of 2023-2031.
  • Infliximab is a monoclonal antibody that is used to treat autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

Retrieved on: 
Mercredi, juin 29, 2022
Review, C5a, FDA, Autoimmunity, III, Patient, European Medicines Agency, CEO, Pyoderma gangrenosum, GLOBE, COVID-19, Company, II, Disease, Blood, End organ damage, Complement, EMA, Food, Receptor (biochemistry), Therapy, Founder, Pyoderma, Survival, Nasdaq, Food and Drug Administration Amendments Act of 2007, PG, Inflammation, Pharmaceutical industry

In addition, the Company had a productive end-of-phase II meeting with the FDA related to its plans for a Phase III development program in PG.

Key Points: 
  • In addition, the Company had a productive end-of-phase II meeting with the FDA related to its plans for a Phase III development program in PG.
  • The Company further reports that Jordan Zwick, Chief Strategy Officer, has left InflaRx to pursue an opportunity in business development.
  • Vilobelimab is believed to be the first monoclonal anti-C5a antibody introduced into clinical development.
  • Vilobelimab is currently being developed for various indications, including pyoderma gangrenosum and severe COVID-19.

InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa

Retrieved on: 
Jeudi, mars 17, 2022
Pyoderma gangrenosum, Letter, Autoimmunity, GLOBE, Hidradenitis suppurativa, Patient, Agency, Therapy, FDA, Nasdaq, Inflammation, COVID-19, CSCC, Pyoderma, Complement, Food, Company, Receptor (biochemistry), Population, Blood, ANCA, End organ damage, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, C5a, Pharmaceutical industry, HS, Phase

We appreciate the prompt feedback from the FDA clarifying the advice received in February, stated Dr. Korinna Pilz, Chief Clinical Development Officer.

Key Points: 
  • We appreciate the prompt feedback from the FDA clarifying the advice received in February, stated Dr. Korinna Pilz, Chief Clinical Development Officer.
  • In light of this corrected advice from FDA, InflaRx believes that further development in HS is feasible.
  • Vilobelimab is currently being developed for various indications, including hidradenitis suppurativa, and has recently reported positive Phase II results in ANCA-associated vasculitis and Phase IIa results in pyoderma gangrenosum.
  • Vilobelimab is in Phase III development for the treatment of critically ill COVID-19 patients and in Phase II development for patients suffering from cutaneous squamous cell carcinoma (cSCC).

InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting

Retrieved on: 
Mardi, mars 8, 2022
Associate, Mayo Clinic, C5a, MA, Patient, American Academy, Complement, CSCC, Inflammation, Blood, ANCA, AAD, COVID-19, Association, PG, Hidradenitis suppurativa, Pyoderma gangrenosum, Receptor (biochemistry), Autoimmunity, Pyoderma, Nasdaq, Clinical professor, GLOBE, Therapy, Pharmaceutical industry, Dermatology

Dr. Alavi will present updated results in her presentation, which will include PG ulcer status during the observational period from the third cohort, along with other outcome measures.

Key Points: 
  • Dr. Alavi will present updated results in her presentation, which will include PG ulcer status during the observational period from the third cohort, along with other outcome measures.
  • Positive data from the third cohort of patients in this study were announced in October 2021.
  • Over 300 people have been treated with vilobelimab in completed clinical trials, and the antibody has been shown to be well tolerated.
  • Vilobelimab is currently being developed for various indications, including hidradenitis suppurativa, and has recently reported positive Phase II results in ANCA-associated vasculitis and pyoderma gangrenosum.

Pyoderma Gangrenosum (PG): 2020 Pipeline Insights Report - ResearchAndMarkets.com

Retrieved on: 
Lundi, avril 20, 2020
Pharmaceutical, Health, Clinical trials, Rare diseases, Medicine, Necrosis, Branches of biology, Gangrene, Pyoderma gangrenosum, Pyoderma, Biology

Pyoderma Gangrenosum (PG) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Pyoderma Gangrenosum (PG) market.

Key Points: 
  • Pyoderma Gangrenosum (PG) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Pyoderma Gangrenosum (PG) market.
  • A detailed picture of the Pyoderma Gangrenosum (PG) pipeline landscape is provided, which includes the disease overview and Pyoderma Gangrenosum (PG) treatment guidelines.
  • The assessment part of the report embraces in-depth Pyoderma Gangrenosum (PG) commercial assessment and clinical assessment of the Pyoderma Gangrenosum (PG) pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Pyoderma Gangrenosum (PG) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Pyoderma Gangrenosum (PG)?

XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies

Retrieved on: 
Vendredi, septembre 20, 2019
Medicine, Organ systems, RTT, Medical specialties, Rare diseases, Gangrene, Necrosis, Pyoderma gangrenosum, Pyoderma, Hidradenitis, Atopic dermatitis, Dermatitis

AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in the treatment of inflammatory skin diseases.

Key Points: 
  • AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in the treatment of inflammatory skin diseases.
  • Stanley Kim, Ph.D., J.D., XBiotechs Corporate Vice President of Intellectual Property, stated, I am pleased that the Canadian Patent Office acknowledged the significance of XBiotechs contribution to this field by granting this patent with broad claims.
  • This patent issuance in Canada further broadens XBiotechs patent portfolio as it relates to bermekimab and its potential to treat inflammatory skin disorders through IL-1 alpha blockade.
  • The company has previously successfully completed clinical studies evaluating bermekimab for treatment of atopic dermatitis, psoriasis1, acne2, pyoderma gangrenosum, and hidradenitis suppurativa3.